MaxCyte announces the signing of a strategic platform license agreement (SPL) with Anocca.
Anocca will deploy MaxCyte’s flow electroporation technology and ExPERT platform to support the scalable development and manufacturing of its deep pipeline of T-cell receptor engineered T-cell (TCR-T) cell therapies.
Under the SPL, Anocca obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s flow electroporation technology and ExPERT platform.
In return, MaxCyte is entitled to receive annual licensing fees and programme-related revenue.
“We’re proud to partner with Anocca as they advance the development of TCR-T therapeutics through the clinic,” said Maher Masoud, President and CEO of MaxCyte.
“We look forward to supporting Anocca with our globally supported, regulatory-proven platform and technical expertise to accelerate clinical manufacturing and cell engineering processes."
"Our ExPERT platform delivers the robust scalability and flexibility needed to power high-performance, non-viral gene editing workflows across Anocca’s diverse therapeutic pipeline.”
Anocca recently received GMP compliance certification and a manufacturing license from Swedish regulators for its cell therapy production facility; its lead programme, targeting mutant KRAS-driven advanced pancreatic cancer, is in clinical development.
With the addition of MaxCyte’s ExPERT platform, Anocca acquires a high-quality, scalable technology platform to enhance its ability to deliver gene-edited cell therapies.